Specialty pharmacy nursing: a promise made by someone else.

1. What a specialty drug and a specialty pharmacy are

“Specialty” has no single legal meaning, but the clearest federal definition is in Medicare Part D. Under 42 CFR 423.104, a specialty tier is a formulary cost-sharing tier dedicated to high-cost Part D drugs whose ingredient cost for a 30-day equivalent supply is greater than a specialty tier cost threshold. CMS sets that threshold for each plan year from prescription drug event data for the plan year that ended 12 months earlier, at the lowest 30-day equivalent ingredient cost within the top 1 percent of all such costs, and changes it only when the computed amount is at least 10 percent above or below the prior year’s threshold. The definition is about cost, not about how the drug is given.

Accreditors describe the pharmacy by its work. URAC’s specialty pharmacy accreditation is for licensed pharmacies that dispense specialty medication and provide patient management services to the patients taking it, and its standards cover patient management, operations, risk management and quality measures. The Accreditation Commission for Health Care describes a specialty pharmacy as one that dispenses injectable, intravenous or oral medications to a patient’s home, a physician’s office or a clinic, specializing in certain disease states, and offers further distinctions for areas such as rare diseases and orphan drugs, oncology and immunoglobulin therapy.

A specialty pharmacy is therefore in the business of managing patients, not only filling prescriptions. The nurse is one of its instruments, often the only one that reaches the patient in person.

2. Limited distribution, the hub and the referral

Many specialty drugs are distributed through a narrow channel. A manufacturer may choose to make a drug available only through one or a few pharmacies, for reasons that can include the size of the patient population, handling requirements, safety programs and the data the manufacturer wants back. A pharmacy in that network is valuable to the manufacturer for its coverage, its reliability and its reporting.

Around the drug there is often a patient-support program, frequently called a hub, run by the manufacturer or a vendor on its behalf. The hub typically enrolls the patient, investigates coverage, coordinates prior authorization and financial assistance, and routes the prescription to a network pharmacy. Where the program includes nursing, either the pharmacy or the hub arranges it, and the nursing referral reaches the agency from whichever of them holds the nursing contract.

For the agency the referral looks like any other, with three additions: a program the visit belongs to, a set of program requirements, and a second audience for the record. The agency has to know which of those applies to each patient before the visit, not after.

3. The visits

Specialty nursing visits fall into three kinds. An injection training visit teaches a patient or caregiver to give a drug they will continue at home, and ends with a return demonstration and a documented judgment that the patient is ready, or a plan for another visit. A first-dose observation visit is a nurse present for the first administration, watching for the reactions the drug’s labeling or the program describes, with emergency preparedness that the prescriber’s order and the agency’s policy define. An ongoing infusion visit is the same anatomy as any home infusion visit, repeated on the therapy’s cycle, sometimes for years.

Each kind has its own documentation, its own rate and its own competency. A nurse who has been checked off on one manufacturer’s injection device is not automatically competent on another’s, and programs frequently ask for evidence of product-specific training. Some first doses are moved to an infusion suite or a clinic where a program or policy requires it.

4. Nurse networks across many states

A pharmacy that ships nationally needs nurses wherever its patients live, so it builds a network: its own nurses where volume justifies them, contracted agencies elsewhere. An agency that covers several states, or a border region, is worth more to that network than one that covers a single metropolitan area.

Licensure decides where a nurse can work. A nurse must be licensed in the state where the patient is located when the care is given. The Nurse Licensure Compact, described on the National Council of State Boards of Nursing’s compact site, lets a registered nurse or licensed practical or vocational nurse whose primary state of residence is a compact state hold one multistate license and practice in other compact states, in person or by telehealth. NCSBN listed 43 jurisdictions in the compact when this page was written in October 2026. The compact does not cover advanced practice registered nurses. A nurse who moves to another compact state must apply for licensure there within 60 days. In a state outside the compact, the agency needs a nurse who holds that state’s license.

The agency’s licensure record therefore has to answer a geographic question for every referral: which nurses may lawfully see a patient at this address. That depends on each nurse’s primary state of residence, whether the license is multistate, whether the patient’s state is in the compact, and whether any license is encumbered. NCSBN’s national licensure database is the usual place to verify the answer.

5. REMS: when the drug brings its own rules

Some specialty drugs carry a Risk Evaluation and Mitigation Strategy. The FDA describes a REMS as a drug safety program it can require for certain medications with serious safety concerns, to help ensure that the benefits of the medication outweigh its risks. A REMS may consist of communication, such as a medication guide for patients and materials for health care providers, and of elements to assure safe use.

Those elements are what reach the nursing visit. According to the FDA they can include certification or training of prescribers, certification of pharmacies, dispensing or administration only in health care settings that have immediate access on site to supplies and personnel, evidence of safe-use conditions such as laboratory results before dispensing, monitoring of patients during or after treatment, and enrollment of patients in a registry. Where a drug’s program restricts the setting of administration or requires monitoring, the pharmacy will tell the agency what that means for the visit, and the agency has to be able to show it was done.

6. Adverse events and product complaints

The nurse is often the first person to see a reaction, a device that failed or a product that looks wrong. FDA’s MedWatch program receives reports of adverse events and product problems for drugs, biologics and devices. Reporting is voluntary for health professionals, who use Form FDA 3500, and for patients and consumers, who use Form 3500B. Manufacturers have mandatory reporting obligations and use Form 3500A. MedWatch also asks for product quality problems such as contamination, defective components, packaging and labeling concerns and suspected counterfeits.

Because the manufacturer carries the mandatory obligation, it pushes the duty to tell it downstream by contract. A specialty pharmacy’s nursing agreement typically requires the agency to report any adverse event or product complaint it learns of to the pharmacy or program within a short, stated period, on the program’s form, and to cooperate with follow-up. That is a contractual duty with a clock, and it applies to events the nurse hears about by telephone as well as those seen at the visit. An agency needs a written procedure, training on it, and a log that shows each report and when it was sent.

What software has to do

A specialty pharmacy relationship is a set of dated obligations attached to each visit. Against the six engines of one operating model, the work divides as follows.

One chain, shared with every other line

A patient, an order, a clinician, a visit, the evidence created, the obligation being satisfied and the money earned are not unrelated records. They are different views of the same operational event.

Specialty pharmacy nursing is the home infusion chain with more parties watching. The patient, the order, the nurse and the visit are the same; what changes is how many organizations the record must answer to and how fast. A platform that keeps the program’s requirements on the same record as the visit lets one nurse serve many programs without many processes. Why this line was the starting point is set out in Why home infusion first.

All service lines →   Continuous compliance →   Interoperability →